Hypertriglyceridemia is a commonly encountered condition for health care providers, it is defined by a fasting serum triglyceride level of more than 150 mg/dl. However, more severe hypertriglyceridemia >1000 mg/dl is rare and found usually in less 1/5000 individuals. (Ford ES, et al, 2009) hypertriglyceridemia can be secondary to few diseases among which is familial lipodystrophy. Triglyceride level of more than 1000 mg/dl is associated with acute pancreatitis, and the risk increases dramatically with increasing triglyceride level to above 2000 mg/dl (reaching 20%) (Scherer J, et al,2014). We present a 39-year-old Caucasian male patient who started to have recurrent acute pancreatitis at the age of 18, investigations for the common causes of acute pancreatitis was unremarkable, except for triglyceride level of 20,000 mg/dl. Genetic testing was consistent with familial partial lipodystrophy. Management initially consisted of plasmapheresis to control the acute episode, in addition to lipid lowering agents (Statin, fenofibrate, and omega-3-acid) .despite being on maximal medical therapy, he required plasmapheresis on weekly basis.His physical exam was remarkable for loss of adipose tissue in the lower extremities and excess adipose tissue deposit in the supra-clavicular area. other metabolic complications included severe insulin resistance and difficult to control DM, and NASH that is progressing to chronic liver disease. The hallmark of lipodystrophy syndromes in general is the selective loss of adipose tissue, which can be partial or complete. Lipodystrophy syndromes are divided into congenital and acquired. Acquired lipodystrophy is most commonly seen is the lipodystrophy secondary to HIV antiretroviral medications (protease inhibitors)(Garg A et.al ,2011). Congenital lipodystrophy remains rare. Our patient has Partial familial lipodystrophy (PFLD), as evident by his physical exam findings. FPLD is also associated with other metabolic abnormalities include hyperglycemia, insulin resistance, increased metabolic rate, and hypertriglyceridemia and that can be severe as in this patient. Conclusion: untreated severe hypertriglyceridemia is an independent risk factor for CAD, as well as a cause of recurrent pancreatitis, which is associated with significant morbidity and mortality, evaluation for secondary causes helps guide the management and prevent serious complications and recurrence.
Familial Partial Lipodystrophy (FPLD) is a rare genetic disorder characterized by loss of subcutaneous adipose tissue mainly from peripheral areas but preservation, or increase, of fat in the face, neck, and trunk. This abnormal fat redistribution leads to a characteristic phenotype and severe metabolic derangements that are difficult to manage. FPLD often present with severe insulin resistance causing type 2 diabetes mellitus (DM2), acanthosis nigricans, hypertriglyceridemia (HTG), and non-alcoholic steatohepatitis (NASH). We present a case of FPLD with severe HTG and HTG induced pancreatitis requiring plasmapheresis, with dramatic metabolic improvements after gastric sleeve surgery. Case presentation: Our patient is a 40-year-old Caucasian male who was diagnosed with DM2 and HTG at age 18 when he presented with pancreatitis. He reported eruptive xanthomas with triglyceride (TG) >3000 mg/dl on the initial presentation. He has central obesity with disproportionately thin extremities and NASH. He has a strong family history of HTG and premature coronary artery disease. He was in a leptin trial; however, he was not included in an extended arm due to deterioration of his metabolic profile, specifically NASH. Despite aggressive therapy with dietary changes, fenofibrate, statin, omega-3, and niacin, he had multiple episodes of pancreatitis with TG levels >5000 mg/dl on many occasions. As a result, he was started on biweekly plasmapheresis that was later changed to weekly. His insulin requirement increased to 450 units daily on U-500. A decision was made for him to proceed with bariatric surgery with his history of insulin-resistant DM2 and morbid obesity. He lost 54 lbs in one year with sleeve gastrectomy and his insulin requirement decreased to 120 units daily. Above all, he had only a single incomplete session of plasmapheresis since his bariatric surgery. He has not required plasmapheresis for over a year so far and his TG levels are consistently <500 mg/dl while only on rosuvastatin 40 mg, with the most recent TG level of 182 mg/dl. Discussion: Bariatric surgery has shown tremendous results in terms of reversal of diabetes and other metabolic derangements. These metabolic benefits are attributed mainly to weight loss in restrictive surgeries and proposed increased GLP-1 levels with Roux-en-Y Gastric Bypass Surgery (RYGB). There are a few case reports of FPLD patients with positive outcomes in terms of metabolic profile with RYGB. In our patient, bariatric surgery was decided due to his DM2 and morbid obesity. He had an unexpected dramatic improvement in the metabolic control of his lipodystrophy. To our knowledge, this is the first case of a FPLD patient with severe HTG requiring plasmapheresis with striking metabolic improvements after sleeve gastrectomy. Gastric sleeve surgery may be an important adjunct or alternative treatment option to the current standard of therapy in patients with FPLD.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.